Remove Pharmaceutical Remove Therapy Remove Treatments
article thumbnail

Distinct Pattern in Protein Production May Predict Severe Side Effects From Melanoma Treatment

The Dermatology Digest

Moreover, the researchers found that this heightened gene signature, as evidenced by the production of spleen tyrosine kinases, or the SYK pathway, did not interfere with the effectiveness of therapies in preventing recurrence of melanoma. The impact was connected only to side effects.

article thumbnail

Done Deal: LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals 

The Dermatology Digest

LEO Pharma now owns TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. All employees of Timber Pharmaceuticals will transition to LEO Pharma’s offices in New Jersey, US, the Company reports. The TMB-001 project continues as planned and without changes within LEO Pharma.

article thumbnail

Ligand Pharmaceuticals Launches Pelthos to Accelerate Commercialization of Zelsuvmi for Molluscum; Appoints New CEO

The Dermatology Digest

Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. Watch Now: Nanette B. in September 2023.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says.

article thumbnail

Multi-Mechanical Therapies with Topicals For Age Management

Lipgloss and Aftershave

By incorporating one microneedling treatment every three months and supporting it with 3 – 4 nano infusion treatments in between, while using topicals with potent ingredients and a proven delivery system professionals provide a comprehensive treatment that delivers visible, long-lasting age management results.

article thumbnail

There’s Something About Eblasakimab: Aslan, Zenyaku Partner to Investigate How it Differs From Other Biologics for AD

The Dermatology Digest

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD). This new agreement expands upon the commercial agreement that Aslan signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.

article thumbnail

Sneak Peek Inside the CSU Treatment Pipeline

The Dermatology Digest

Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.